FORM 6-K
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of November 2007
Commission File Number 1-15182
DR. REDDYS LABORATORIES LIMITED
(Name of Registrant)
7-1-27, Ameerpet
Hyderabad, Andhra Pradesh 500 016, India
+91-40-23731946
(Address of Principal Executive Offices)
Indicate by check mark whether registrant files or will file annual reports under cover of Form
20-F or Form 40-F.
Form 20-F þ Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrants home country), or under the rules of the home country
exchange on which the registrants securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrants
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes o No þ
If Yes is marked, indicate below the file number assigned to registrant in connection with Rule
12g3-2(b):
Not applicable.
Table of Contents
(1) |
|
Press Release, SYGNIS AG and DR. REDDYS sign exclusive supply
collaboration for AX200 in stroke, November 26, 2007. |
|
(2) |
|
Press Release, Argenta Discovery and Dr. Reddys progress
pre-clinical anti-inflammatory candidate to treat chronic
respiratory disease, November 26, 2007. |
2
|
|
|
Press Release
|
|
|
|
|
|
|
|
|
|
Dr. Reddys Laboratories Ltd. |
|
|
7-1-27 Ameerpet |
|
|
Hyderabad 500 016 India |
|
|
|
|
|
Tel: 91 40 373 1946 |
|
|
Fax: 91 40 373 1955 |
|
|
|
|
|
www.drreddys.com |
Heidelberg, Germany and Hyderabad, India, 26 November 2007
SYGNIS AG and DR. REDDYS sign exclusive supply collaboration for AX200 in stroke
Agreement with Dr. Reddys secures long-term supply to advance the clinical development of
SYGNIS lead product candidate
Dr. Reddys first agreement for the long-term supply of a biological molecule; First of its kind
from India
Heidelberg, Germany and Hyderabad, India, 26 November 2007 SYGNIS Pharma AG (Frankfurt: LIO; ISIN
DE0005043509; Prime Standard) and the leading Indian phar-maceutical company Dr. Reddys
Laboratories (NYSE: RDY) today announced the sign-ing of an exclusive 10 year agreement for the
supply of the active ingredient AX200, a biological molecule in development by SYGNIS for the
treatment of Stroke and other neurodegenerative disorders. The Agreement secures the supply of
AX200 far beyond the clinical development and provides a solid basis for the envisaged marketing of
the compound.
SYGNIS successfully completed a Phase IIa clinical trial of AX200 in September, that demonstrated
safety and efficacy in patients with acute Stroke. In the second half of 2008, SYGNIS plans to
start a Phase IIb efficacy trial in acute Stroke with AX200 sup-plied by Dr. Reddys. Stroke
affects over 5 million patients worldwide every year and is the third leading cause of death,
presenting a major socio-economic burden.
Dr. Alfred Bach, Chief Executive Officer, SYGNIS Pharma AG, said, Our collaboration with Dr.
Reddys represents an important milestone in the development of AX200 which we believe has
potential to significantly improve the treatment perspective for millions of patients globally. The
long-term access to secure production sources for AX200 is a major step on SYGNIS way to becoming
a product-focused company. This provides us with the flexibility to optimize our marketing strategy
for this product. The fact that Dr. Reddys entered into this collaboration also reflects their
confidence in the enormous potential of AX200.
Dr. Cartikeya Reddy, Head of Biologics at Dr. Reddys, said, Biopharmaceutical Ser-vices is a fast
growing business segment globally with a limited number of service pro-viders. Our strategic
decision to exclusively produce a biological molecule for a partner is a first in the history of
Dr. Reddys and fits very well within our Custom Pharmaceutical Services business model. We are
very optimistic that AX200 will continue to show real potential in the treatment of Acute Stroke
with the potential to be used in the treatment of other degenerative neurological diseases.
SYGNIS Pharma AG Contact Information:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de
Dr. Reddys Contact Information:
Custom Pharmaceutical Services Europe:
Marcel Velterop at marcelvelterop@drreddys.com or on +41 (0)797733453
Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-23731946 ext. 308
Media:
Mythili Mamidanna at at mythilim@drreddys.com or on +91-40-66511620
3
About AX200
AX200 for the treatment of acute stroke is the most advanced drug candidate in SYG-NIS product
pipeline. The AX200 protein is produced at highly elevated levels in the brain, as part of an
endogenous protective mechanism after brain damage. Thus, if this drug administered in the acute
phase of Stroke, the brains own protective action is fur-ther boosted. This offers a highly
beneficial, dual neurotherapeutic approach which has been discovered by SYGNIS. AX200 stops
neuronal cell death in the acute phase of Stroke, and in addition, it stimulates the regeneration
of the already damaged nervous tissue through the stimulation of neurogenesis as well as
arteriogenesis and the reor-ganisation of neuronal networks. Besides Stroke, AX200 is currently in
preclinical testing for further neurodegenerative indications such as Amyotrophic Lateral Sclerosis
(ALS).
About SYGNIS Pharma
SYGNIS Pharma AG, with head offices in Heidelberg, is a specialty pharmaceutical Company listed on
the Prime Standard of the German stock exchange. The Company is focused on the research,
development and marketing of innovative therapies for the treatment of neurodegenerative diseases.
These include stroke, Amyotrophic Lateral Sclerosis (ALS), Huntingtons Disease and neurological
disorders resulting from injury, such as trauma of the brain or spinal cord. All these disorders
are characterized by the fact that, as the disease progresses, nerve cells are damaged and die.
Although there is great medical demand, there are currently no or only inadequate treatment options
available.
About Dr. Reddys
Established in 1984, Dr. Reddys Laboratories (NYSE: RDY) is an emerging global pharmaceutical
company with proven research capabilities. The Company is vertically integrated with a presence
across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical
ingredients and biotechnology products and mar-kets them globally, with focus on India, US, Europe
and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular,
inflammation and bacterial infection. ( www.drreddys.com )
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand for our products, our
growth and expansion, technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially different from actual
results in the future.
4
|
|
|
Press Release
|
|
|
|
|
|
|
|
|
|
Dr. Reddys Laboratories Ltd. |
|
|
7-1-27 Ameerpet |
|
|
Hyderabad 500 016 India |
|
|
|
|
|
Tel: 91 40 373 1946 |
|
|
Fax: 91 40 373 1955 |
|
|
|
|
|
www.drreddys.com |
Harlow, UK and Hyderabad, India, 26 November 2007
Argenta Discovery and Dr Reddys progress pre-clinical anti-inflammatory candidate to treat chronic
respiratory disease
Harlow, UK and Hyderabad, India; 26 November 2007 Argenta Discovery Limited, the respiratory drug
discovery and development company, and Dr Reddys Laboratories (NYSE: RDY), today announce a major
milestone in their development programme targeting a novel disease-modifying approach to treat the
underlying cause of certain chronic respiratory diseases including chronic obstructive pulmonary
disease (COPD) and severe asthma.
Argentas Chief Executive Officer, Dr. Christopher Ashton said: Just 18 months after signing the
deal with Dr Reddys, the team has already selected the first candidate drug to proceed into
pre-clinical development. We are very excited by the exceptional progress this programme has made
within such a short timeframe. With GMP material already manufactured we are on target to enter
Phase I in mid-2008 and Phase II in 2009. We believe we are first-in-class for this inhaled
anti-inflammatory approach to treat chronic respiratory disease.
Under the terms of the licensing agreement announced in February 2006, Argenta and Dr Reddys are
collaborating to identify clinical candidates against an undisclosed but proven anti-inflammatory
drug target and to develop these candidates to Phase II proof-of-concept.
Ashton added: The programme is also likely to deliver high quality back-up candidates in the near
future, which is testament to the overall strength and depth of the approach. This rapid progress
towards the clinic is further validation that Argentas innovative fast forward strategy for the
rapid development of new respiratory medicines against well validated, precedented drug targets has
achieved significant momentum. We are building a strong pipeline and have the funds to take all our
programmes as far as clinical proof-of-concept.
Notes to Editors
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow
obstruction that is progressive and current therapies, including inhaled corticosteroids, fail to
treat disease progression. COPD is a leading cause of morbidity and mortality worldwide with an
overall prevalence in adults over 40 years currently estimated at between 9 and 10%. Unlike many
other major diseases, deaths due to COPD are increasing and the World Health Organisation (WHO)
estimates by 2020 COPD will be the third leading cause of mortality and the fifth leading cause of
morbidity in the world. Thus, there is a high level of unmet medical need for this progressive and
debilitating disease.
About Dr Reddys
Established in 1984, Dr. Reddys Laboratories (NYSE: RDY) is an emerging global pharmaceutical
company with proven research capabilities. The Company is vertically integrated with a presence
across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical
ingredients and biotechnology products and markets them globally, with focus on India, US, Europe
and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular,
inflammation and bacterial infection. (www.drreddys.com)
About Argenta Discovery
Founded in August 2000, Argenta has leading expertise in chronic respiratory diseases, including
Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. The company has generated a
portfolio of pre-clinical anti-inflammatory programmes with the goal of taking these as far as
Phase IIa proof-of-concept. In November 2006, Argenta initiated its first clinical trial with
ADC4022, an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease
(COPD) and severe asthma.
Argenta also has a successful and growing contract research division that provides integrated drug
discovery services to a range of leading pharmaceutical and biotechnology companies worldwide.
Argenta employs approximately 150 people and is based in Harlow and Slough, UK.
(www.argentadiscovery.com)
5
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand for our products, our
growth and expansion, technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially different from actual
results in the future.
Contact Information
Dr. Reddys:
Investor Relations: Nikhil Shah at nikhilshah@drreddys.com or on +91-40-23731946 ext. 308
Media: M Mythili at mythilim@drreddys.com or on +91-40-66511620
Argenta Discovery :
Chris Ashton at chris.ashton@argentadiscovery.com or on +44 (0) 1279 645 645
6
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DR. REDDYS LABORATORIES LIMITED |
|
|
|
|
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ V. Viswanath |
|
|
|
|
|
|
|
|
|
Date: December 5, 2007
|
|
|
|
Name:
|
|
V. Viswanath |
|
|
|
|
|
|
Title:
|
|
Company Secretary |
|
|
|
|
|
|
|
|
|
|
|
7